Transcatheter tricuspid repair cut death or heart failure admission by 60% over three years

The edition in brief

In TRIC-I-HF (NEJM), transcatheter tricuspid repair plus medical therapy beat medical therapy alone in 360 patients with symptomatic severe tricuspid regurgitation, mean age 80: win ratio 2.42 at one year and HR 0.40 for death or heart failure admission through three years. CONDUCT-AF, an 82-patient European trial, found left bundle branch area pacing non-inferior to biventricular pacing for LVEF improvement six months after AV node ablation, with shorter procedures. A meta-analysis of six RCTs found primary-prevention ICDs in nonischaemic HFrEF lowered sudden death (RR 0.41) and cardiovascular death (RR 0.75) but not all-cause death (RR 0.88, CI crossing 1). A network meta-analysis of 27 trials ranked candesartan and telmisartan as the ARBs with MACE reduction, though comparisons were mostly indirect. TARTAN-HF found NT-proBNP screening in high-risk diabetes diagnosed heart failure in one in four, mostly HFpEF. The pearl covers reading NT-proBNP in obesity, AF and CKD.